Implantica AG (IMP-A-SDB.ST)
SEK 26.85
(-5.95%)
SEK 26.85
(-5.95%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 1.4 Million EUR | 67.22% |
| 2022 | 842 Thousand EUR | 117.57% |
| 2021 | 387 Thousand EUR | 154.61% |
| 2020 | 152 Thousand EUR | 442.86% |
| 2019 | 28 Thousand EUR | 56.71% |
| 2018 | 17.86 Thousand EUR | 0.0% |
| 2017 | - EUR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 554 Thousand EUR | -7.05% |
| 2024 Q1 | 596 Thousand EUR | 17.32% |
| 2023 Q1 | 307 Thousand EUR | 26.86% |
| 2023 FY | 1.4 Million EUR | 67.22% |
| 2023 Q4 | 508 Thousand EUR | 108.2% |
| 2023 Q3 | 244 Thousand EUR | -30.09% |
| 2023 Q2 | 349 Thousand EUR | 13.68% |
| 2022 Q4 | 242 Thousand EUR | 24.1% |
| 2022 Q3 | 195 Thousand EUR | -5.8% |
| 2022 Q2 | 207 Thousand EUR | 4.55% |
| 2022 FY | 842 Thousand EUR | 117.57% |
| 2022 Q1 | 198 Thousand EUR | 85.05% |
| 2021 Q3 | 83 Thousand EUR | -27.83% |
| 2021 Q2 | 115 Thousand EUR | 40.24% |
| 2021 Q1 | 82 Thousand EUR | 215.38% |
| 2021 Q4 | 107 Thousand EUR | 28.92% |
| 2021 FY | 387 Thousand EUR | 154.61% |
| 2020 FY | 152 Thousand EUR | 442.86% |
| 2020 Q2 | 76 Thousand EUR | 230.43% |
| 2020 Q4 | 26 Thousand EUR | -3.7% |
| 2020 Q3 | 27 Thousand EUR | -64.47% |
| 2020 Q1 | 23 Thousand EUR | 228.57% |
| 2019 Q3 | - EUR | 0.0% |
| 2019 Q4 | 7000.00 EUR | 0.0% |
| 2019 FY | 28 Thousand EUR | 56.71% |
| 2018 FY | 17.86 Thousand EUR | 0.0% |
| 2017 FY | - EUR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Acarix AB (publ) | 6.24 Million SEK | 77.44% |
| ADDvise Group AB (publ) | 1.37 Billion SEK | 99.897% |
| ADDvise Group AB (publ) | 1.37 Billion SEK | 99.897% |
| Arcoma AB | 163.01 Million SEK | 99.136% |
| Bactiguard Holding AB (publ) | 203.99 Million SEK | 99.31% |
| BICO Group AB (publ) | 2.23 Billion SEK | 99.937% |
| Boule Diagnostics AB (publ) | 571.32 Million SEK | 99.754% |
| CellaVision AB (publ) | 677.29 Million SEK | 99.792% |
| Clinical Laserthermia Systems AB (publ) | 8.27 Million SEK | 82.981% |
| Chordate Medical Holding AB (publ) | 976.28 Thousand SEK | -44.221% |
| C-Rad AB (publ) | 424.61 Million SEK | 99.668% |
| Duearity AB (publ) | 1.65 Million SEK | 14.873% |
| Dignitana AB (publ) | 86.06 Million SEK | 98.364% |
| Episurf Medical AB (publ) | 10.3 Million SEK | 86.33% |
| Getinge AB (publ) | 31.82 Billion SEK | 99.996% |
| Scandinavian Real Heart AB (Publ) | - SEK | -Infinity% |
| Iconovo AB (publ) | 7.07 Million SEK | 80.108% |
| Integrum AB (publ) | 104.11 Million SEK | 98.648% |
| Luxbright AB (publ) | 854.69 Thousand SEK | -64.736% |
| Mentice AB (publ) | 273.61 Million SEK | 99.485% |
| OssDsign AB (publ) | 112.15 Million SEK | 98.745% |
| Paxman AB (publ) | 210.11 Million SEK | 99.33% |
| Promimic AB (publ) | 37.07 Million SEK | 96.202% |
| Qlife Holding AB (publ) | 244 Thousand SEK | -477.049% |
| SciBase Holding AB (publ) | 23.24 Million SEK | 93.943% |
| ScandiDos AB (publ) | 60.42 Million SEK | 97.67% |
| Sectra AB (publ) | 2.96 Billion SEK | 99.952% |
| Sedana Medical AB (publ) | 153.86 Million SEK | 99.085% |
| Senzime AB (publ) | 35.75 Million SEK | 96.062% |
| SpectraCure AB (publ) | 318 Thousand SEK | -342.767% |
| Stille AB | 294.89 Million SEK | 99.523% |
| Vitrolife AB (publ) | 3.51 Billion SEK | 99.96% |
| Xvivo Perfusion AB (publ) | 597.54 Million SEK | 99.764% |